<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03149874</url>
  </required_header>
  <id_info>
    <org_study_id>BN-0517</org_study_id>
    <nct_id>NCT03149874</nct_id>
  </id_info>
  <brief_title>Accelerated Vaccination Schedule Against Hepatitis B Virus With Combined Hepatitis A and B Vaccine Among Hemodialysis Patients</brief_title>
  <official_title>Accelerated Vaccination Schedule Against Hepatitis B Virus With Combined Hepatitis A and B Vaccine Among Hemodialysis Patients, Does it Works?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New Jeddah Clinic Hospital</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to examine the result of seroprotection using the accelerated
      vaccination schedule in vaccination of hemodialysis patient through using combined hepatitis
      A and B vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2014</start_date>
  <completion_date type="Actual">May 1, 2017</completion_date>
  <primary_completion_date type="Actual">April 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Patient seuentially randomized to either vaccine</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatitis B virus Seroprotection after one month</measure>
    <time_frame>one month after third dose of the vaccine</time_frame>
    <description>Hepatitis B virus surface antibodies titer after one month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatitis B virus Seroprotection after three months</measure>
    <time_frame>three months after third dose of the vaccine</time_frame>
    <description>Hepatitis B virus surface antibodies titer after three month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fever</measure>
    <time_frame>4 Days after each vaccination dose</time_frame>
    <description>The proportion of fever among patients in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scale</measure>
    <time_frame>1 Hour after each vaccination dose</time_frame>
    <description>Visual pain scale for pain from injection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Hemodialysis Complication</condition>
  <arm_group>
    <arm_group_label>Hepatitis B recombinant DNA vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each Hepatitis B recombinant DNA vaccine vial contained 20 microgram of vaccine dose. Two vials will be intramuscularly injected one vial in each deltoid muscle on months zero, one, two and six.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined hepatitis A and B vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each one-milliliter dose of vaccine contains 720 ELISA units of inactivated hepatitis A virus and 20 mcg of recombinant HBsAg protein. One dose of vaccine also contains 0.45 mg of aluminum. Two vials will be intramuscularly injected one vial in each deltoid muscle on on days zero, seven, and 21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hepatitis B Vaccines</intervention_name>
    <description>either Hepatitis B recombinant DNA vaccine or Combined hepatitis A and B vaccine given to the patients</description>
    <arm_group_label>Hepatitis B recombinant DNA vaccine</arm_group_label>
    <arm_group_label>Combined hepatitis A and B vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age was above 18 years

          -  Hemodialysis patient

          -  All patients had undetectable hepatitis B virus surface antigen and antibody

        Exclusion Criteria:

          -  A positive serum hepatitis B virus surface antigen and antibody

          -  patient received a previous course of hepatitis B virus vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Mahmoud Hamada imam</investigator_full_name>
    <investigator_title>MD. - Lecturer at Internal Medicine Department- Faculty of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

